Stronger Avian Flu Vaccine From GlaxoSmithKline
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on July 27, 2006
GlaxoSmithKline reports the results of clinical trials of its vaccine against bird flu, which has demonstrated that more than 80% of the subjects were protected by two shots, each containing only 3.8 micrograms of an antigen. This is a far better performance than the current vaccine on stockpile -- which is manufactured by Sanofi-Pasteur-- which demonstrated 50% protection after two doses of 90 micrograms each.
According to a New York Times article, GlaxoSmithKline will seek regulatory approval from the FDA this year, and if approved, the avian flu vaccine will sell for the same price as a standard flu shot, i.e., $8 to $12 a shot.
Read the full story here.

Tags: vaccine flu biotech avian glaxosmithkline avian+vaccine stronger+avian food+agriculture
Vote for Stronger Avian Flu Vaccine From GlaxoSmithKline:
|
Rating: 6.00 out of 1 vote(s) cast.
|
Response from:
Trusted.MD Network
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
